In this video, Motley Fool health care analyst Brenton Flynn highlights a couple of emerging trends that medical technology investors should be watching. The first thing he has his eye on is a new procedure called renal denervation, a method to treat patients with hypertension who don't respond to medication. His second area to watch is how different pharmaceutical and biotech companies push into emerging markets, and how they address the need for more value-oriented solutions in these areas.
Brenton Flynn has no positions in the stocks mentioned above. The Motley Fool owns shares of Johnson & Johnson, Medtronic, and St. Jude Medical. Motley Fool newsletter services recommend Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.